Advertisement

Topics

Lutonix, Inc. Company Profile

04:04 EST 22nd November 2017 | BioPortfolio

Restenosis is the re-narrowing of an artery experienced by some patients following angioplasty, atherectomy, or stenting. Restenosis is caused by an overgrowth of tissue inside the artery wall at the original treatment site. Restenosis is typically experienced by some patients within the first 6 months of treatment, which most often results in re-intervention or surgery.


News Articles [3 Associated News Articles listed on BioPortfolio]

C. R. Bard, Inc. Snags FDA Premarket Approval of The Lutonix 035 Drug Coated Balloon As The First And Only DCB

  Life Sciences Jobs   ...

Mercy Medical Center First Hospital in Maryland to Utilize New FDA Approved Drug-Coated Balloon Catheter for Treatment of Arteriovenous Fistulas

Baltimore, MD (PRWEB) October 12, 2017 Alain Tanbe, M.D., a fellowship-trained vascular surgeon at The Vascular Center at Mercy M...

C. R. Bard Receives FDA Premarket Approval of the LUTONIX® 035 Drug Coated Balloon as the First and Only DCB for the Treatment of Patients with Dysfunctional AV Fistulae

New Option to Preserve Vascular Access and Help Hemodialysis Patients Extend Time Between Reinterventions C. R. Bard, Inc. (NYSE:BCR) today announced the LUTONIX® 035 Drug Co...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [9 Associated Clinical Trials listed on BioPortfolio]

LEVANT I, The Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropoliteal Restenosis

The purpose of the study is to assess the safety and efficacy of the Lutonix Catheter for treatment of stenosis of the femoropopliteal arteries by direct comparison to standard balloon ang...

De Novo Pilot Study, Lutonix Catheter in Conjunction With Bare Metal Stenting for Treatment of Coronary De Novo Lesions

The study will enroll patients with angiographically significant coronary de novo lesions. Subjects will be randomized 1:1 and treated with a Lutonix catheter either before or after bare-m...

Lutonix or Inpact for tHE tReatment Of fEmeropopliteal Stenosis - DCB

Investigators hypothesize in patients presenting with significant peripheral arterial disease with clinical indications for treatment with angioplasty, there will be a difference in 12 mon...

Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon for Treatment of BTK Arteries

The study will enroll patients presenting with claudication, or critical limb ischemia (Rutherford Category 3- 5) and an angiographically significant (≥ 70%) native artery lesion appropr...

Study Comparing Lutonix AV Drug Coated Balloon vs Standard Balloon for Treatment of Dysfunctional AV Fistulae

This prospective, global, multicenter, randomized, controlled study is designed to evaluate the safety and effectiveness of the Lutonix 035 AV Drug Coated Balloon PTA Catheter compared to ...

Companies [1 Associated Companies listed on BioPortfolio]

Lutonix, Inc.

Restenosis is the re-narrowing of an artery experienced by some patients following angioplasty, atherectomy, or stenting. Restenosis is caused by an overgrowth of tissue inside the artery wall at the...

More Information about "Lutonix, Inc." on BioPortfolio

We have published hundreds of Lutonix, Inc. news stories on BioPortfolio along with dozens of Lutonix, Inc. Clinical Trials and PubMed Articles about Lutonix, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Lutonix, Inc. Companies in our database. You can also find out about relevant Lutonix, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record